AVI-4015 is under clinical development by Enzychem Lifesciences and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AVI-4015’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AVI-4015 overview

AVI-4015 is under development for the treatment of keratoconjunctivitis sicca (dry eye). It is administered through ophthalmic route in the form of eye drops. The drug candidate is a repositioning drug acts by targeting DDR1 receptor and is developed based on advanced cell-penetrating peptide (ACP), that delivers the therapeutic drug.

Enzychem Lifesciences overview

Enzychem Lifesciences (Enzychem) develops and produces novel drugs and active pharmaceutical ingredients (APIs). The company is developing new drugs to treat diseases like asthma, psoriasis, rheumatoid arthritis, atopic dermatitis, acute radiation syndrome, sepsis, and autoimmune disorders. The company’s pipeline product EC-18 is being developed for the treatment of cancer and inflammation. Enzychem servers the patients across the globe. It has research and development center in Chungcheongbuk-do, South Korea. The company has its operations in South Korea and the USA. The company is headquartered in Seocho-gu, Seoul, South Korea.

For a complete picture of AVI-4015’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.